Morningstar

Altamira Therapeutics Ltd CYTO

Morningstar Rating

Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray

GlobeNewswire Sep 27, 2024 1:01pm
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results

GlobeNewswire Sep 24, 2024 12:01pm
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024

GlobeNewswire Sep 20, 2024 1:01pm
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering

GlobeNewswire Sep 19, 2024 8:01pm
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering

GlobeNewswire Sep 17, 2024 9:00pm
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia

GlobeNewswire Sep 16, 2024 12:30pm
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11

GlobeNewswire Sep 3, 2024 1:01pm
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark

GlobeNewswire Aug 23, 2024 1:01pm
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances

GlobeNewswire Aug 16, 2024 1:01pm
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models

GlobeNewswire Aug 12, 2024 1:02pm
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles

GlobeNewswire Jul 19, 2024 1:01pm

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.